Clinical Assistant Professor
University of Calgary
University of Calgary
Calgary, Alberta, Canada
Dr. James Kim is a Clinical Assistant Professor in the Department of Family Medicine at the University of Calgary with a special interest in diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic migraine. Since completing his Master’s program in Healthcare Professional Education, Dr. Kim’s interest lies in effective healthcare professional education delivery methods and has been invited as a guest lecturer at a number of universities and conferences on this topic. He is also a lead editor for the Primary Care section of Canadian Journal of Diabetes .
Within Diabetes Canada, his role includes steering committee member for the Clinical Practice Guidelines; current co-chair of Primary Care Special Interest Group; Dissemination and Implementation member; author of the guidelines; lead author of MASLD guidelines.
Within Migraine Canada, Dr. Kim is a scientific committee member and he is a committee member of the international medical education organization. Most recently, he was invited to join the Global NASH Council, as one of the first Canadian member, to collaborate with the leading international experts on MASLD. He is currently leading a major project in Calgary to reduce the wait time to access the specialists.
AS2402 - Enhancing Uptake and Use of Glucose Sensing Technology
Thursday, November 21, 2024
12:45 - 13:45 AT Time
Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Abbvie: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Eisai: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); EMBECTA: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); GSK: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Idorsia: Consultant (Ongoing); Lin Pharma: Advisory Board (Ongoing); MDBriefcase: Committee/Planning Member (Terminated); Novo Nordisk Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Otsuka: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Searchlight: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Takeda Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Teva: Speaker/Honoraria (Ongoing)
CC08 - The Cardiometabolic Impact of Insomnia
Thursday, November 21, 2024
17:35 - 17:55 AT Time
Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Abbvie: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Eisai: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); EMBECTA: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); GSK: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Idorsia: Consultant (Ongoing); Lin Pharma: Advisory Board (Ongoing); MDBriefcase: Committee/Planning Member (Terminated); Novo Nordisk Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Otsuka: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Searchlight: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Takeda Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Teva: Speaker/Honoraria (Ongoing)
Friday, November 22, 2024
08:15 - 09:30 AT Time
Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Abbvie: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Eisai: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); EMBECTA: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); GSK: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Idorsia: Consultant (Ongoing); Lin Pharma: Advisory Board (Ongoing); MDBriefcase: Committee/Planning Member (Terminated); Novo Nordisk Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Otsuka: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Searchlight: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Takeda Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Teva: Speaker/Honoraria (Ongoing)
DC2421 - Scientific Oral Abstracts (Clinical)
Friday, November 22, 2024
16:00 - 17:15 AT Time
Disclosure information not submitted.
DC2428 - All Things New: Hot topics from 2024
Saturday, November 23, 2024
08:15 - 09:30 AT Time
Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Abbvie: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Eisai: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); EMBECTA: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); GSK: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Idorsia: Consultant (Ongoing); Lin Pharma: Advisory Board (Ongoing); MDBriefcase: Committee/Planning Member (Terminated); Novo Nordisk Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Otsuka: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Searchlight: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Takeda Canada: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Teva: Speaker/Honoraria (Ongoing)